At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $251.36M, lower than 95% of all stocks globally
- PositionReturn on equity is -986.3%, lower than 95% of its Biotechnology peers (median -21.1%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
251.36MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.46xvs all stocks
52-Week Change
80.49%vs all stocks
Forward Annual Dividend Yield
0.00%vs all stocks
Market Capitalization
251.36MUSDvs all stocks (USD)
Enterprise Value
226.42MUSDvs all stocks (USD)
Forward P/E
-19.55xvs Biotechnology peers
Price to Book (MRQ)
75.61xvs Biotechnology peers
Enterprise to EBITDA
-9.99xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-235.98%vs Biotechnology peers
Return on Equity (TTM)
-986.32%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Oct 27, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-22.66MUSDvs all stocks (USD)
Net Income (TTM)
-22.47MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-12.49MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-3.34MUSDvs all stocks (USD)
Forward Annual Dividend Yield
0.00%vs all stocks
Trailing Annual Dividend Rate
0.00USDUpdated Oct 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-19.45MUSDvs all stocks (USD)
Pre-tax Income
-19.36MUSDFY2025 · Dec 31, 2025Net Income
-19.36MUSDFY2025 · Dec 31, 2025EBIT
-19.45MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-19.45MUSDFY2025 · Dec 31, 2025Research & Development
17.22MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
2.23MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
89.70KUSDFY2025 · Dec 31, 2025EPS (Basic)
-1.43USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.43USDFY2025 · Dec 31, 2025Basic Shares Outstanding
13.53MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
13.53MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-19.36MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-10.11MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
6.18MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-19.36MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.78KUSDFY2025 · Dec 31, 2025Stock-based Compensation
6.80MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
2.07MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
367.54KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
11.85MUSDFY2025 · Dec 31, 2025Shares Outstanding
14.68MSharesUpdated Oct 27, 2026Float Shares
7.65MSharesUpdated Oct 27, 2026Shares Short
1.58MSharesUpdated Oct 27, 2026Short Ratio
13.74daysvs all stocks
Short % of Shares Outstanding
20.66%vs all stocks
% Held by Insiders
47.91%vs all stocks
% Held by Institutions
12.26%vs all stocks
Total Cash (MRQ)
8.88MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.6050USDUpdated Oct 27, 2026Total Debt (MRQ)
0.00USDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.00xvs Biotechnology peers
Current Ratio (MRQ)
1.54xvs Biotechnology peers
Book Value per Share (MRQ)
0.2120USDUpdated Oct 27, 2026Total Assets
6.18MUSDvs all stocks (USD)
Total Current Assets
6.18MUSDFY2025 · Dec 31, 2025Total Liabilities
5.82MUSDFY2025 · Dec 31, 2025Total Non-current Assets
0.00USDFY2025 · Dec 31, 2025Total Non-current Liabilities
0.00USDFY2025 · Dec 31, 2025Total Current Liabilities
5.82MUSDFY2025 · Dec 31, 2025Cash
6.18MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
6.18MUSDFY2025 · Dec 31, 2025Accounts Payable
4.87MUSDFY2025 · Dec 31, 2025Deferred Revenue
673.82KUSDFY2025 · Dec 31, 2025Common Stock (Book)
14.30KUSDFY2025 · Dec 31, 2025Retained Earnings
-87.14MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
353.22KUSDvs all stocks (USD)
52-Week Low
7.78USDUpdated Oct 27, 202652-Week High
34.10USDUpdated Oct 27, 202652-Week Change
80.49%vs all stocks
Beta
1.46xvs all stocks
50-Day MA
16.65USDUpdated Oct 27, 2026200-Day MA
21.76USDUpdated Oct 27, 2026Avg 10-Day Volume
132.54KSharesUpdated Oct 27, 2026Avg 30-Day Volume
132.22KSharesUpdated Oct 27, 2026Diluted EPS (TTM)
-1.53USDUpdated Oct 27, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is -986.3%, lower than 95% of its Biotechnology peers (median -21.1%)Significant
Return on equity: -9.86Industry median: -0.21Industry P5: -1.59Peers compared: 245
Return on assets is -236%, lower than 95% of its Biotechnology peers (median -18.4%)Significant
Return on assets: -2.36Industry median: -0.18Industry P5: -0.75Peers compared: 245
Price-to-book is 75.61×, higher than 95% of its Biotechnology peers (median 2.68×)Significant
Price-to-book: 75.61Industry median: 2.68Industry P95: 15.61Peers compared: 245
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)Notable
Debt-to-equity: 0.00Industry median: 0.09Industry P5: 0.00Peers compared: 245
Structural Tensions
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 1.54Altman Z-Score: -4.17
Financial Health
Altman Z-Score -4.17: distress zoneCritical
Altman Z-Score: -4.17
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $251.36M, lower than 95% of all stocks globallySignificant
Market cap (USD): 251,364,312Global P5: 273,689,256.68
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 37,231,057.061
Companies that share the same coordination system — how they create, deliver, or capture value.
Abeona Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Larimar Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Jiangsu GDK Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Lyell Immunopharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Elite Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Daito Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ocugen Inc.
Tier 1ProductionApproval-Gated PipelineRule
Heartseed Inc.
Tier 1ProductionApproval-Gated PipelineRule
PharmaEngine, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hangzhou Jiuyuan Gene Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow